SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Medical ImagingNuclear Medical

PUBLISHER: Meticulous Research | PRODUCT CODE: 2132829

Cover Image

PUBLISHER: Meticulous Research | PRODUCT CODE: 2132829

Radioligand Therapy Market by Product/Radioligand, Radionuclide, Radiation Type, Molecular Target, Indication, Treatment Line, Route of Administration, End User, and Geography - Global Forecast to 2036

PUBLISHED:
PAGES: 321 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4175
PDF & Excel (Multi User License)
USD 5875
PDF & Excel (Global Site License)
USD 7875

Add to Cart

Description

Table of Contents

List of Tables

The global Radioligand Therapy Market was valued at USD 3.1 billion in 2025 and is estimated at USD 3.9 billion in 2026, and is projected to reach USD 11.8 billion by 2036, expanding at a CAGR of 11.7% during the forecast period. The report provides a comprehensive evaluation of the rapidly evolving radioligand therapy market by examining clinical adoption trends, label expansions, radionuclide supply and manufacturing dynamics, reimbursement frameworks, and competitive strategies shaping this segment of the precision oncology landscape.

Radioligand therapy is a form of targeted radiopharmaceutical therapy in which a targeting molecule, such as a peptide, small molecule, or antibody, is linked through a chelator or linker to a therapeutic radionuclide that delivers cytotoxic radiation directly to tumors while limiting exposure of surrounding healthy tissue. Most radioligand therapies are developed as theranostic pairs, in which a closely related diagnostic radiotracer is used with PET or SPECT imaging to confirm target expression, select patients, estimate dosimetry, and monitor response. The rising prevalence of prostate cancer and neuroendocrine tumors, expanding clinical evidence supporting earlier-line use, and rising investment in alpha-emitter radionuclide platforms are driving the adoption of these therapies across oncology and nuclear medicine settings worldwide.

This report delivers an in-depth assessment of the market by analyzing molecular target innovation, radionuclide supply dynamics, regulatory approvals, manufacturing infrastructure investment, and competitive positioning shaping industry growth. It evaluates how advances in alpha-emitter development, theranostic pairing, and companion diagnostic imaging are improving patient selection and expanding eligible patient populations. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business, investment, and healthcare technology decisions.

Market Dynamics

The rising global burden of cancer remains one of the primary drivers of the radioligand therapy market. As prostate cancer and neuroendocrine tumors continue to represent a significant share of the global cancer burden, healthcare providers are increasingly adopting radioligand therapies as targeted treatment options with demonstrated survival benefits, particularly as these treatments move from later-line into earlier treatment settings. The FDA's March 2025 approval of Pluvicto for pre-taxane metastatic castration-resistant prostate cancer, followed by its July 2026 approval in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, has substantially expanded the eligible patient population. Growing adoption of biomarker-driven precision oncology and the expanding availability of PSMA PET and somatostatin receptor imaging agents are further supporting market growth.

Continuous investment activity is reshaping the competitive landscape, particularly around alpha-emitting radionuclides such as actinium-225 and lead-212, which offer higher relative biological effectiveness than conventional beta emitters. Strategic acquisitions, including large pharmaceutical company purchases of alpha-emitter platform developers, alongside the buildout of dedicated radiopharmaceutical manufacturing facilities, are improving production capacity and shortening delivery timelines to treatment centers. Continued research into molecular targets beyond PSMA and SSTR, including fibroblast activation protein, gastrin-releasing peptide receptor, integrins, and HER2, is also expected to broaden the application scope of radioligand therapy into additional solid tumor types.

Despite favorable market conditions, several challenges continue to influence industry adoption. Limited global production capacity for key therapeutic radionuclides such as lutetium-177 and actinium-225, combined with the complex, time-critical supply chains required for short half-life isotopes, remains an important constraint on market scale-up. Specialized radiolabeling facilities, stringent quality control requirements, high treatment costs, and the need for coordinated nuclear medicine infrastructure add further operational complexity, while shortages of trained nuclear medicine professionals, regulatory complexity across countries, and uneven reimbursement decisions continue to limit broader adoption in certain regions.

The market nevertheless presents substantial long-term opportunities. Continued expansion into earlier lines of cancer treatment, growing development of alpha-particle radioligand therapies, the emergence of new molecular targets, and increasing adoption across emerging markets are expected to create favorable conditions for future market growth. As healthcare systems continue to invest in nuclear medicine infrastructure and precision oncology, demand for advanced radioligand therapies is expected to increase significantly across both developed and emerging healthcare markets.

Segment Analysis

The report provides detailed market analysis across product/radioligand, radionuclide, radiation type, molecular target, indication, treatment line, end user, and geography, enabling stakeholders to identify high-growth business opportunities and evolving oncology treatment trends.

Based on product/radioligand, the market is segmented into Pluvicto, Lutathera, Xofigo, lutetium-177 edotreotide (ITM-11), 177Lu-PSMA-I&T, actinium-225 PSMA-617, FPI-2265, TLX591, 225Ac-DOTATATE (RYZ101), AlphaMedix, 67Cu-SAR-bisPSMA, and other radioligand therapies. In 2026, Pluvicto is expected to account for the largest share of the global market, reflecting its position as the only approved PSMA-targeted radioligand therapy in major markets and successive label expansions into earlier treatment settings. The other radioligand therapies segment is projected to register the highest growth during the forecast period, supported by the expected approval of radioligands directed at new targets such as fibroblast activation protein and expansion into cancers beyond prostate cancer and neuroendocrine tumors.

By radionuclide and radiation type, the market is analyzed across lutetium-177, actinium-225, radium-223, lead-212, and other radionuclides, and across beta emitters, alpha emitters, and other emitters including Auger electron emitters. Lutetium-177 and beta emitters are each expected to account for a largest share of the market in 2026, reflecting their use in Pluvicto and Lutathera and in most late-stage investigational products. The alpha emitters segment is projected to register the highest growth during the forecast period, driven by the anticipated approvals of actinium-225 and lead-212 therapies and by major pharmaceutical investments in alpha-emitter platforms.

From a molecular target perspective, the report evaluates PSMA, SSTR, bone mineral (hydroxyapatite), FAP, and other emerging targets. PSMA-targeted radioligands represent the largest segment, with a 69.8% share in 2026, supported by the commercial success of Pluvicto, high PSMA expression across most prostate cancers, and the broad availability of PSMA PET imaging. By indication and treatment line, prostate cancer is expected to account for 76.3% of the market in 2026, while first-line therapy is projected to register the highest CAGR of 25.8% as radioligand therapies move into metastatic hormone-sensitive prostate cancer and earlier systemic treatment of advanced neuroendocrine tumors.

The report also analyzes market performance across academic & comprehensive cancer centers, community hospitals, specialized nuclear medicine centers, and other end users. Academic and comprehensive cancer centers account for the largest share in 2026 due to their established nuclear medicine infrastructure, PET imaging capacity, radiopharmacy expertise, and role in clinical trials, while specialized nuclear medicine centers are expected to witness the fastest growth as investment in dedicated outpatient theranostics capacity continues to expand.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider cancer prevalence, nuclear medicine infrastructure, radiopharmaceutical manufacturing capacity, regulatory pathways, and reimbursement frameworks influencing market growth.

North America is expected to account for the largest share of the global radioligand therapy market in 2026, supported by leading radioligand therapy developers, established nuclear medicine and PSMA PET infrastructure, expanding domestic manufacturing capacity, established Medicare and private insurance coverage, and a regulatory environment that has enabled rapid label expansions for approved therapies. Europe with Germany as the largest European market as labels expand and new products launch, while national reimbursement decisions continue to shape patient access.

Asia-Pacific is projected to register the highest growth throughout the forecast period, supported by regulatory approvals across Japan, Australia, and China, planned regional manufacturing investment, large aging populations, and growing adoption of molecular imaging and precision oncology. China is expected to overtake Japan as the largest Asia-Pacific market by 2036. Latin America and the Middle East & Africa are also expected to present emerging growth opportunities as nuclear medicine infrastructure and cancer care access continue to improve.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their product pipelines, radionuclide supply strategies, manufacturing capacity investments, partnerships, acquisitions, and recent business developments.

The commercial radioligand therapy market is currently highly concentrated. Based on reported commercial sales, Novartis AG (Switzerland) ranked first in the global radioligand therapy market in 2025, followed by Bayer AG (Germany). Curium, ITM, Bristol Myers Squibb, and Telix are best positioned to become the next commercial competitors based on their late-stage programs. Competitive benchmarking enables stakeholders to evaluate companies based on clinical trial data, radionuclide supply security, manufacturing capacity, molecular target differentiation, regulatory approvals, and commercialization strategies. The study also analyzes how market participants are leveraging strategic acquisitions and manufacturing partnerships to secure access to constrained therapeutic radionuclides and build differentiated pipelines within the radioligand therapy space.

Key companies profiled in the report include Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Bristol Myers Squibb Company (U.S.), AstraZeneca PLC (U.K.), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), Curium (U.K.), Lantheus Holdings, Inc. (U.S.), Perspective Therapeutics, Inc. (U.S.), Orano Med (France), RadioMedix, Inc. (U.S.), Clarity Pharmaceuticals Ltd (Australia), and Sanofi (France). The key strategies followed by these companies between 2023 and 2026 were clinical and regulatory milestones, agreements, partnerships, and licensing, acquisitions, and manufacturing and isotope production expansions.

How This Report Helps

  • Provides accurate market size estimates and long-term forecasts for the global radioligand therapy market.
  • Evaluates the impact of molecular target innovation, alpha-emitter development, and theranostic pairing on market growth.
  • Identifies high-growth opportunities across products, radionuclides, radiation types, molecular targets, indications, treatment lines, end users, and geographic regions.
  • Analyzes radionuclide supply and manufacturing capacity trends, regulatory developments, and reimbursement frameworks shaping market growth.
  • Benchmarks leading companies based on pipeline depth, radionuclide supply strategy, manufacturing footprint, and competitive positioning.
  • Supports product development, investment planning, partnership evaluation, market entry, and business expansion strategies.
  • Delivers actionable market intelligence for radiopharmaceutical manufacturers, oncology healthcare providers, nuclear medicine specialists, investors, and healthcare organizations.

Key Questions Answered

  • What is the current size of the global radioligand therapy market, and how is it expected to evolve through 2036?
  • Which clinical, technological, and regulatory factors are driving market growth?
  • What are the major drivers, restraints, opportunities, and challenges influencing industry development?
  • Which product, radionuclide, radiation type, molecular target, indication, treatment line, end-user, and regional segments are expected to experience the strongest growth?
  • How are label expansions into earlier lines of treatment reshaping the eligible patient population and revenue outlook?
  • What is the outlook for alpha-emitter radioligand therapies, and how will radionuclide supply constraints affect commercialization?
  • Which geographic markets present the most attractive business opportunities?
  • Who are the leading companies operating in the market, and what competitive strategies are they adopting?
  • What recent regulatory approvals, acquisitions, and manufacturing investments are shaping the competitive landscape?
  • How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, and long-term business strategy?
Show more
Product Code: MRHC - 1042150

TABLE OF CONTENTS

  • Table of Contents

1 INTRODUCTION

  • 1.1 Market Definition
  • 1.2 Market Ecosystem
  • 1.3 Currency and Limitations
    • 1.3.1 Currency
    • 1.3.2 Limitations
  • 1.4 Key Stakeholders

2 RESEARCH METHODOLOGY

  • 2.1 Research Approach
  • 2.2 Data Collection & Validation Process
    • 2.2.1 Secondary Research
    • 2.2.2 Primary Research & Validation
      • 2.2.2.1 Primary Interviews with Radioligand Therapy Experts
      • 2.2.2.2 Country-/Region-Level Analysis
  • 2.3 Market Estimation
    • 2.3.1 Bottom-Up Approach
    • 2.3.2 Top-Down Approach
    • 2.3.3 Forecast Methodology
  • 2.4 Data Triangulation
  • 2.5 Assumptions

3 EXECUTIVE SUMMARY

4 MARKET OVERVIEW

  • 4.1 Introduction
  • 4.2 Radioligand Therapy Overview
    • 4.2.1 Radioligand Therapy Concept
    • 4.2.2 Targeted Radionuclide Therapy
    • 4.2.3 Diagnostic-Therapeutic Pairing
    • 4.2.4 Theranostics
    • 4.2.5 Radioligand Therapy Treatment Workflow
    • 4.2.6 Patient Selection
    • 4.2.7 Dosimetry
    • 4.2.8 Administration & Treatment Monitoring
  • 4.3 Radioligand Therapy Components
    • 4.3.1 Targeting Ligands
    • 4.3.2 Chelators
    • 4.3.3 Radionuclides
    • 4.3.4 Linkers
    • 4.3.5 Carrier Molecules
    • 4.3.6 Diagnostic Counterparts
  • 4.4 Market Dynamics
    • 4.4.1 Drivers
      • 4.4.1.1 Increasing Prevalence of Cancer
      • 4.4.1.2 Growing Clinical Adoption of PSMA- and SSTR-Targeted Therapies
      • 4.4.1.3 Increasing Adoption of Precision Oncology and PET-Based Patient Selection
      • 4.4.1.4 Growing Pharmaceutical Investments in Radioligand Therapy
    • 4.4.2 Restraints
      • 4.4.2.1 Limited Availability of Therapeutic Radionuclides
      • 4.4.2.2 Complex Manufacturing and Time-Critical Supply Chains
      • 4.4.2.3 High Treatment Costs and Limited Nuclear Medicine Infrastructure
    • 4.4.3 Opportunities
      • 4.4.3.1 Expansion into Earlier Lines of Treatment
      • 4.4.3.2 Development of Alpha-Emitter Radioligand Therapies
      • 4.4.3.3 Emergence of New Molecular Targets Beyond Prostate Cancer and Neuroendocrine Tumors
      • 4.4.3.4 Increasing Adoption in Emerging Markets
    • 4.4.4 Challenges
      • 4.4.4.1 Shortage of Trained Nuclear Medicine Workforce
      • 4.4.4.2 Regulatory Complexity Across Countries
      • 4.4.4.3 Patient Access and Reimbursement Challenges
  • 4.5 Regulatory Landscape
    • 4.5.1 U.S. Regulatory Landscape
    • 4.5.2 European Regulatory Landscape
    • 4.5.3 Asia-Pacific Regulatory Landscape
    • 4.5.4 Radiopharmaceutical Manufacturing Requirements
    • 4.5.5 Good Manufacturing Practices
    • 4.5.6 Radiation Safety Regulations
    • 4.5.7 Clinical Trial Requirements
    • 4.5.8 Companion Diagnostic Requirements
  • 4.6 Reimbursement Landscape
    • 4.6.1 Reimbursement for Radioligand Therapy
    • 4.6.2 Reimbursement for Diagnostic Imaging
    • 4.6.3 Hospital-Based Reimbursement
    • 4.6.4 Private Insurance Coverage
    • 4.6.5 Government Reimbursement Programs
    • 4.6.6 Patient Access Programs
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Bargaining Power of Buyers
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Threat of Substitutes
    • 4.7.4 Threat of New Entrants
    • 4.7.5 Degree of Competition
  • 4.8 Investment & Industry Trends
    • 4.8.1 Pharmaceutical Investments in Radioligand Therapy
    • 4.8.2 Radiopharmaceutical Manufacturing Investments
    • 4.8.3 Radionuclide Production Investments
    • 4.8.4 Alpha-Emitter Investments
    • 4.8.5 Radioligand Therapy Acquisitions
    • 4.8.6 Strategic Partnerships & Licensing
    • 4.8.7 Expansion of Nuclear Medicine Infrastructure
    • 4.8.8 Clinical Pipeline Expansion

5 RADIOLIGAND THERAPY MARKET, BY PRODUCT/RADIOLIGAND

  • 5.1 Introduction
  • 5.2 Lutetium-177 Vipivotide Tetraxetan (Pluvicto)
  • 5.3 Lutetium-177 Dotatate (Lutathera)
  • 5.4 Radium-223 Dichloride (Xofigo)
  • 5.5 Lutetium-177 Edotreotide (ITM-11)
  • 5.6 Lutetium-177 Zadavotide Guraxetan (177Lu-PSMA-I&T)
  • 5.7 Actinium-225 PSMA-617
  • 5.8 FPI-2265
  • 5.9 TLX591 (177Lu-Rosopatamab Tetraxetan)
  • 5.10 225Ac-DOTATATE (RYZ101)
  • 5.11 212Pb-DOTAMTATE (AlphaMedix)
  • 5.12 67Cu-SAR-bisPSMA
  • 5.13 Other Radioligand Therapies

6 RADIOLIGAND THERAPY MARKET, BY RADIONUCLIDE

  • 6.1 Introduction
  • 6.2 Lutetium-177 (Lu-177)
  • 6.3 Actinium-225 (Ac-225)
  • 6.4 Radium-223 (Ra-223)
  • 6.5 Lead-212 (Pb-212)
  • 6.6 Other Radionuclides

7 RADIOLIGAND THERAPY MARKET, BY RADIATION TYPE

  • 7.1 Introduction
  • 7.2 Beta Emitters
  • 7.3 Alpha Emitters
  • 7.4 Other Emitters (Including Auger Electron Emitters)

8 RADIOLIGAND THERAPY MARKET, BY MOLECULAR TARGET

  • 8.1 Introduction
  • 8.2 Prostate-Specific Membrane Antigen (PSMA)
  • 8.3 Somatostatin Receptors (SSTR)
  • 8.4 Bone Mineral (Hydroxyapatite)
  • 8.5 Fibroblast Activation Protein (FAP)
  • 8.6 Other Emerging Targets

9 RADIOLIGAND THERAPY MARKET, BY INDICATION

  • 9.1 Introduction
  • 9.2 Prostate Cancer
    • 9.2.1 Metastatic Castration-Resistant Prostate Cancer
    • 9.2.2 Metastatic Hormone-Sensitive Prostate Cancer
  • 9.3 Neuroendocrine Tumors
    • 9.3.1 Gastrointestinal Neuroendocrine Tumors
    • 9.3.2 Pancreatic Neuroendocrine Tumors
    • 9.3.3 Lung & Other Neuroendocrine Tumors
  • 9.4 Other Solid Tumors
  • 9.5 Other Indications

10 RADIOLIGAND THERAPY MARKET, BY TREATMENT LINE

  • 10.1 Introduction
  • 10.2 First-Line Therapy
  • 10.3 Second-Line Therapy
  • 10.4 Third-Line & Later Therapy

11 RADIOLIGAND THERAPY MARKET, BY END USER

  • 11.1 Introduction
  • 11.2 Academic & Comprehensive Cancer Centers
  • 11.3 Community Hospitals
  • 11.4 Specialized Nuclear Medicine Centers
  • 11.5 Other End Users

12 RADIOLIGAND THERAPY MARKET, BY GEOGRAPHY

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 U.K.
    • 12.3.3 France
    • 12.3.4 Italy
    • 12.3.5 Spain
    • 12.3.6 Switzerland
    • 12.3.7 Netherlands
    • 12.3.8 Belgium
    • 12.3.9 Sweden
    • 12.3.10 Rest of Europe
  • 12.4 Asia-Pacific
    • 12.4.1 China
    • 12.4.2 Japan
    • 12.4.3 India
    • 12.4.4 South Korea
    • 12.4.5 Australia
    • 12.4.6 Singapore
    • 12.4.7 Taiwan
    • 12.4.8 Rest of Asia-Pacific
  • 12.5 Latin America
    • 12.5.1 Brazil
    • 12.5.2 Mexico
    • 12.5.3 Argentina
    • 12.5.4 Rest of Latin America
  • 12.6 Middle East & Africa
    • 12.6.1 U.A.E.
    • 12.6.2 Saudi Arabia
    • 12.6.3 Israel
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 COMPETITIVE LANDSCAPE

  • 13.1 Overview
  • 13.2 Key Growth Strategies
  • 13.3 Competitive Benchmarking
  • 13.4 Competitive Dashboard
    • 13.4.1 Market Leaders
    • 13.4.2 Market Differentiators
    • 13.4.3 Vanguards
    • 13.4.4 Emerging Players
  • 13.5 Market Ranking Analysis, By Key Player (2025)
    • 13.5.1 Novartis AG (Switzerland) - Rank 1
    • 13.5.2 Bayer AG (Germany) - Rank 2
    • 13.5.3 Next Commercial Challengers

14 COMPANY PROFILES

  • 14.1 Novartis AG
    • 14.1.1 Business Overview
    • 14.1.2 Financial Overview
    • 14.1.3 Radioligand Therapy Portfolio
    • 14.1.4 Pipeline
    • 14.1.5 Manufacturing Capabilities
    • 14.1.6 Strategic Developments
    • 14.1.7 SWOT Analysis
  • 14.2 Bayer AG
    • 14.2.1 Business Overview
    • 14.2.2 Financial Overview
    • 14.2.3 Radioligand Therapy Portfolio
    • 14.2.4 Pipeline
    • 14.2.5 Manufacturing Capabilities
    • 14.2.6 SWOT Analysis
  • 14.3 Eli Lilly and Company
    • 14.3.1 Business Overview
    • 14.3.2 Financial Overview
    • 14.3.3 Radioligand Therapy Portfolio
    • 14.3.4 Pipeline
    • 14.3.5 Manufacturing Capabilities
    • 14.3.6 Strategic Developments
    • 14.3.7 SWOT Analysis
  • 14.4 Bristol Myers Squibb Company (RayzeBio)
    • 14.4.1 Business Overview
    • 14.4.2 Financial Overview
    • 14.4.3 Radioligand Therapy Portfolio
    • 14.4.4 Pipeline
    • 14.4.5 Manufacturing Capabilities
    • 14.4.6 Strategic Developments
    • 14.4.7 SWOT Analysis
  • 14.5 AstraZeneca PLC (Fusion Pharmaceuticals)
    • 14.5.1 Business Overview
    • 14.5.2 Financial Overview
    • 14.5.3 Radioligand Therapy Portfolio
    • 14.5.4 Pipeline
    • 14.5.5 Manufacturing Capabilities
    • 14.5.6 Strategic Developments
    • 14.5.7 SWOT Analysis
  • 14.6 Telix Pharmaceuticals Limited
    • 14.6.1 Business Overview
    • 14.6.2 Financial Overview
    • 14.6.3 Radioligand Therapy Portfolio
    • 14.6.4 Pipeline
    • 14.6.5 Manufacturing Capabilities
    • 14.6.6 Strategic Developments
    • 14.6.7 SWOT Analysis
  • 14.7 ITM Isotope Technologies Munich SE
    • 14.7.1 Business Overview
    • 14.7.2 Radioligand Therapy Portfolio
    • 14.7.3 Pipeline
    • 14.7.4 Manufacturing Capabilities
    • 14.7.5 Strategic Developments
    • 14.7.6 SWOT Analysis
  • 14.8 Curium
    • 14.8.1 Business Overview
    • 14.8.2 Radioligand Therapy Portfolio
    • 14.8.3 Pipeline
    • 14.8.4 Manufacturing Capabilities
    • 14.8.5 Strategic Developments
    • 14.8.6 SWOT Analysis
  • 14.9 Lantheus Holdings, Inc.
    • 14.9.1 Business Overview
    • 14.9.2 Financial Overview
    • 14.9.3 Radioligand Therapy Portfolio
    • 14.9.4 Pipeline
    • 14.9.5 Manufacturing Capabilities
    • 14.9.6 Strategic Developments
    • 14.9.7 SWOT Analysis
  • 14.10 Perspective Therapeutics, Inc.
    • 14.10.1 Business Overview
    • 14.10.2 Financial Overview
    • 14.10.3 Radioligand Therapy Portfolio
    • 14.10.4 Pipeline
    • 14.10.5 Manufacturing Capabilities
    • 14.10.6 Strategic Developments
    • 14.10.7 SWOT Analysis
  • 14.11 Orano Med
    • 14.11.1 Business Overview
    • 14.11.2 Radioligand Therapy Portfolio
    • 14.11.3 Pipeline
    • 14.11.4 Manufacturing Capabilities
    • 14.11.5 Strategic Developments
    • 14.11.6 SWOT Analysis
  • 14.12 RadioMedix, Inc.
    • 14.12.1 Business Overview
    • 14.12.2 Radioligand Therapy Portfolio
    • 14.12.3 Pipeline
    • 14.12.4 Manufacturing Capabilities
    • 14.12.5 Strategic Developments
    • 14.12.6 SWOT Analysis
  • 14.13 Clarity Pharmaceuticals Ltd
    • 14.13.1 Business Overview
    • 14.13.2 Financial Overview
    • 14.13.3 Radioligand Therapy Portfolio
    • 14.13.4 Pipeline
    • 14.13.5 Manufacturing Capabilities
    • 14.13.6 Strategic Developments
    • 14.13.7 SWOT Analysis
  • 14.14 Sanofi
    • 14.14.1 Business Overview
    • 14.14.2 Financial Overview
    • 14.14.3 Radioligand Therapy Portfolio
    • 14.14.4 Pipeline
    • 14.14.5 Strategic Developments
    • 14.14.6 SWOT Analysis

15 APPENDIX

  • 15.1 Related Reports
  • 15.2 Customization Options
Show more
Product Code: MRHC - 1042150

LIST OF TABLES

List of Tables

  • Table 1. Global Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 2. Global Radioligand Therapy Market for Pluvicto, By Country/Region, 2024-2036 (USD Million)
  • Table 3. Global Radioligand Therapy Market for Lutathera, By Country/Region, 2024-2036 (USD Million)
  • Table 4. Global Radioligand Therapy Market for Xofigo, By Country/Region, 2024-2036 (USD Million)
  • Table 5. Global Radioligand Therapy Market for Lutetium-177 Edotreotide, By Country/Region, 2024-2036 (USD Million)
  • Table 6. Global Radioligand Therapy Market for 177Lu-PSMA-I&T, By Country/Region, 2024-2036 (USD Million)
  • Table 7. Global Radioligand Therapy Market for Actinium-225 PSMA-617, By Country/Region, 2024-2036 (USD Million)
  • Table 8. Global Radioligand Therapy Market for FPI-2265, By Country/Region, 2024-2036 (USD Million)
  • Table 9. Global Radioligand Therapy Market for TLX591, By Country/Region, 2024-2036 (USD Million)
  • Table 10. Global Radioligand Therapy Market for 225Ac-DOTATATE, By Country/Region, 2024-2036 (USD Million)
  • Table 11. Global Radioligand Therapy Market for AlphaMedix, By Country/Region, 2024-2036 (USD Million)
  • Table 12. Global Radioligand Therapy Market for 67Cu-SAR-bisPSMA, By Country/Region, 2024-2036 (USD Million)
  • Table 13. Global Radioligand Therapy Market for Other Radioligand Therapies, By Country/Region, 2024-2036 (USD Million)
  • Table 14. Global Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 15. Global Lutetium-177 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 16. Global Actinium-225 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 17. Global Radium-223 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 18. Global Lead-212 Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 19. Global Radioligand Therapy Market for Other Radionuclides, By Country/Region, 2024-2036 (USD Million)
  • Table 20. Global Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 21. Global Beta Emitter Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 22. Global Alpha Emitter Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 23. Global Radioligand Therapy Market for Other Emitters, By Country/Region, 2024-2036 (USD Million)
  • Table 24. Global Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 25. Global PSMA-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 26. Global SSTR-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 27. Global Bone Mineral-Targeted Radiopharmaceutical Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 28. Global FAP-Targeted Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 29. Global Radioligand Therapy Market for Other Emerging Targets, By Country/Region, 2024-2036 (USD Million)
  • Table 30. Global Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 31. Global Radioligand Therapy Market for Prostate Cancer, By Type, 2024-2036 (USD Million)
  • Table 32. Global Radioligand Therapy Market for Prostate Cancer, By Country/Region, 2024-2036 (USD Million)
  • Table 33. Global Radioligand Therapy Market for Neuroendocrine Tumors, By Type, 2024-2036 (USD Million)
  • Table 34. Global Radioligand Therapy Market for Neuroendocrine Tumors, By Country/Region, 2024-2036 (USD Million)
  • Table 35. Global Radioligand Therapy Market for Other Solid Tumors, By Country/Region, 2024-2036 (USD Million)
  • Table 36. Global Radioligand Therapy Market for Other Indications, By Country/Region, 2024-2036 (USD Million)
  • Table 37. Global Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 38. Global First-Line Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 39. Global Second-Line Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 40. Global Third-Line & Later Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 41. Global Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 42. Global Radioligand Therapy Market for Academic & Comprehensive Cancer Centers, By Country/Region, 2024-2036 (USD Million)
  • Table 43. Global Radioligand Therapy Market for Community Hospitals, By Country/Region, 2024-2036 (USD Million)
  • Table 44. Global Radioligand Therapy Market for Specialized Nuclear Medicine Centers, By Country/Region, 2024-2036 (USD Million)
  • Table 45. Global Radioligand Therapy Market for Other End Users, By Country/Region, 2024-2036 (USD Million)
  • Table 46. Global Radioligand Therapy Market, By Region, 2024-2036 (USD Million)
  • Table 47. Global Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 48. North America: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 49. North America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 50. North America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 51. North America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 52. North America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 53. North America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 54. North America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 55. North America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 56. U.S.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 57. U.S.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 58. U.S.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 59. U.S.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 60. U.S.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 61. U.S.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 62. U.S.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 63. Canada: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 64. Canada: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 65. Canada: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 66. Canada: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 67. Canada: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 68. Canada: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 69. Canada: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 70. Europe: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 71. Europe: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 72. Europe: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 73. Europe: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 74. Europe: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 75. Europe: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 76. Europe: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 77. Europe: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 78. Germany: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 79. Germany: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 80. Germany: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 81. Germany: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 82. Germany: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 83. Germany: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 84. Germany: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 85. U.K.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 86. U.K.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 87. U.K.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 88. U.K.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 89. U.K.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 90. U.K.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 91. U.K.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 92. France: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 93. France: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 94. France: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 95. France: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 96. France: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 97. France: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 98. France: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 99. Italy: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 100. Italy: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 101. Italy: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 102. Italy: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 103. Italy: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 104. Italy: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 105. Italy: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 106. Spain: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 107. Spain: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 108. Spain: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 109. Spain: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 110. Spain: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 111. Spain: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 112. Spain: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 113. Switzerland: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 114. Switzerland: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 115. Switzerland: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 116. Switzerland: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 117. Switzerland: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 118. Switzerland: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 119. Switzerland: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 120. Netherlands: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 121. Netherlands: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 122. Netherlands: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 123. Netherlands: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 124. Netherlands: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 125. Netherlands: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 126. Netherlands: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 127. Belgium: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 128. Belgium: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 129. Belgium: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 130. Belgium: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 131. Belgium: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 132. Belgium: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 133. Belgium: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 134. Sweden: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 135. Sweden: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 136. Sweden: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 137. Sweden: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 138. Sweden: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 139. Sweden: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 140. Sweden: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 141. Rest of Europe: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 142. Rest of Europe: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 143. Rest of Europe: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 144. Rest of Europe: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 145. Rest of Europe: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 146. Rest of Europe: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 147. Rest of Europe: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 148. Asia-Pacific: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 149. Asia-Pacific: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 150. Asia-Pacific: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 151. Asia-Pacific: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 152. Asia-Pacific: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 153. Asia-Pacific: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 154. Asia-Pacific: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 155. Asia-Pacific: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 156. China: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 157. China: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 158. China: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 159. China: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 160. China: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 161. China: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 162. China: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 163. Japan: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 164. Japan: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 165. Japan: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 166. Japan: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 167. Japan: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 168. Japan: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 169. Japan: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 170. India: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 171. India: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 172. India: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 173. India: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 174. India: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 175. India: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 176. India: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 177. South Korea: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 178. South Korea: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 179. South Korea: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 180. South Korea: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 181. South Korea: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 182. South Korea: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 183. South Korea: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 184. Australia: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 185. Australia: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 186. Australia: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 187. Australia: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 188. Australia: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 189. Australia: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 190. Australia: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 191. Singapore: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 192. Singapore: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 193. Singapore: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 194. Singapore: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 195. Singapore: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 196. Singapore: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 197. Singapore: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 198. Taiwan: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 199. Taiwan: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 200. Taiwan: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 201. Taiwan: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 202. Taiwan: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 203. Taiwan: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 204. Taiwan: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 205. Rest of Asia-Pacific: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 206. Rest of Asia-Pacific: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 207. Rest of Asia-Pacific: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 208. Rest of Asia-Pacific: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 209. Rest of Asia-Pacific: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 210. Rest of Asia-Pacific: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 211. Rest of Asia-Pacific: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 212. Latin America: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 213. Latin America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 214. Latin America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 215. Latin America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 216. Latin America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 217. Latin America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 218. Latin America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 219. Latin America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 220. Brazil: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 221. Brazil: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 222. Brazil: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 223. Brazil: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 224. Brazil: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 225. Brazil: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 226. Brazil: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 227. Mexico: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 228. Mexico: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 229. Mexico: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 230. Mexico: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 231. Mexico: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 232. Mexico: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 233. Mexico: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 234. Argentina: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 235. Argentina: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 236. Argentina: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 237. Argentina: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 238. Argentina: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 239. Argentina: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 240. Argentina: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 241. Rest of Latin America: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 242. Rest of Latin America: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 243. Rest of Latin America: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 244. Rest of Latin America: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 245. Rest of Latin America: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 246. Rest of Latin America: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 247. Rest of Latin America: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 248. Middle East & Africa: Radioligand Therapy Market, By Country/Region, 2024-2036 (USD Million)
  • Table 249. Middle East & Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 250. Middle East & Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 251. Middle East & Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 252. Middle East & Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 253. Middle East & Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 254. Middle East & Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 255. Middle East & Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 256. U.A.E.: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 257. U.A.E.: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 258. U.A.E.: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 259. U.A.E.: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 260. U.A.E.: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 261. U.A.E.: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 262. U.A.E.: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 263. Saudi Arabia: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 264. Saudi Arabia: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 265. Saudi Arabia: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 266. Saudi Arabia: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 267. Saudi Arabia: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 268. Saudi Arabia: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 269. Saudi Arabia: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 270. Israel: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 271. Israel: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 272. Israel: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 273. Israel: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 274. Israel: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 275. Israel: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 276. Israel: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 277. South Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 278. South Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 279. South Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 280. South Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 281. South Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 282. South Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 283. South Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 284. Rest of Middle East & Africa: Radioligand Therapy Market, By Product/Radioligand, 2024-2036 (USD Million)
  • Table 285. Rest of Middle East & Africa: Radioligand Therapy Market, By Radionuclide, 2024-2036 (USD Million)
  • Table 286. Rest of Middle East & Africa: Radioligand Therapy Market, By Radiation Type, 2024-2036 (USD Million)
  • Table 287. Rest of Middle East & Africa: Radioligand Therapy Market, By Molecular Target, 2024-2036 (USD Million)
  • Table 288. Rest of Middle East & Africa: Radioligand Therapy Market, By Indication, 2024-2036 (USD Million)
  • Table 289. Rest of Middle East & Africa: Radioligand Therapy Market, By Treatment Line, 2024-2036 (USD Million)
  • Table 290. Rest of Middle East & Africa: Radioligand Therapy Market, By End User, 2024-2036 (USD Million)
  • Table 291. Recent Developments, By Company (2023-2026)
  • Table 292. Radioligand Therapy Market: Competitive Benchmarking, By Radionuclide
  • Table 293. Radioligand Therapy Market: Competitive Benchmarking, By Molecular Target
  • Table 294. Radioligand Therapy Market: Competitive Benchmarking, By Commercial & Development Stage
  • Table 295. Novartis AG: Radioligand Therapy Portfolio
  • Table 296. Novartis AG: Strategic Developments (2023-2026)
  • Table 297. Bayer AG: Radioligand Therapy Portfolio
  • Table 298. Eli Lilly and Company: Radioligand Therapy Portfolio
  • Table 299. Eli Lilly and Company: Strategic Developments (2023-2026)
  • Table 300. Bristol Myers Squibb Company: Radioligand Therapy Portfolio
  • Table 301. Bristol Myers Squibb Company: Strategic Developments (2023-2026)
  • Table 302. AstraZeneca PLC: Radioligand Therapy Portfolio
  • Table 303. AstraZeneca PLC: Strategic Developments (2023-2026)
  • Table 304. Telix Pharmaceuticals Limited: Radioligand Therapy and Theranostics Portfolio
  • Table 305. Telix Pharmaceuticals Limited: Strategic Developments (2023-2026)
  • Table 306. ITM Isotope Technologies Munich SE: Radioligand Therapy Portfolio
  • Table 307. ITM Isotope Technologies Munich SE: Strategic Developments (2023-2026)
  • Table 308. Curium: Radioligand Therapy Portfolio
  • Table 309. Curium: Strategic Developments (2023-2026)
  • Table 310. Lantheus Holdings, Inc.: Radioligand Therapy and Theranostics Portfolio
  • Table 311. Lantheus Holdings, Inc.: Strategic Developments (2023-2026)
  • Table 312. Perspective Therapeutics, Inc.: Radioligand Therapy Portfolio
  • Table 313. Perspective Therapeutics, Inc.: Strategic Developments (2023-2026)
  • Table 314. Orano Med: Radioligand Therapy Portfolio
  • Table 315. Orano Med: Strategic Developments (2023-2026)
  • Table 316. RadioMedix, Inc.: Radioligand Therapy Portfolio
  • Table 317. RadioMedix, Inc.: Strategic Developments (2023-2026)
  • Table 318. Clarity Pharmaceuticals Ltd: Radioligand Therapy and Theranostics Portfolio
  • Table 319. Clarity Pharmaceuticals Ltd: Strategic Developments (2023-2026)
  • Table 320. Sanofi: Radioligand Therapy Portfolio
  • Table 321. Sanofi: Strategic Developments (2023-2026)

LIST OF FIGURES

List of Figures

  • Figure 1. Radioligand Therapy Market Ecosystem
  • Figure 2. Currency Conversion Rates Used in the Study (Annual Average Exchange Rates, 2024-2025)
  • Figure 3. Key Stakeholders in the Radioligand Therapy Market
  • Figure 4. Research Process
  • Figure 5. Secondary Sources Referenced for This Study
  • Figure 6. Primary Research Techniques
  • Figure 7. Key Executives Interviewed
  • Figure 8. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 9. Market Sizing and Growth Forecast Approach
  • Figure 10. Data Triangulation
  • Figure 11. Global Radioligand Therapy Market, By Product/Radioligand, 2026 Vs. 2036 (USD Million)
  • Figure 12. Global Radioligand Therapy Market, By Radionuclide, 2026 Vs. 2036 (USD Million)
  • Figure 13. Global Radioligand Therapy Market, By Radiation Type, 2026 Vs. 2036 (USD Million)
  • Figure 14. Global Radioligand Therapy Market, By Molecular Target, 2026 Vs. 2036 (USD Million)
  • Figure 15. Global Radioligand Therapy Market, By Indication, 2026 Vs. 2036 (USD Million)
  • Figure 16. Global Radioligand Therapy Market, By Treatment Line, 2026 Vs. 2036 (USD Million)
  • Figure 17. Global Radioligand Therapy Market, By End User, 2026 Vs. 2036 (USD Million)
  • Figure 18. Global Radioligand Therapy Market, By Geography, 2026 Vs. 2036 (USD Million)
  • Figure 19. Radioligand Therapy Treatment Workflow
  • Figure 20. Components of a Radioligand Therapy
  • Figure 21. Impact Analysis of Market Dynamics
  • Figure 22. Regulatory Framework for Radioligand Therapy
  • Figure 23. Porter's Five Forces Analysis - Radioligand Therapy Market
  • Figure 24. Global Radioligand Therapy Market, By Product/Radioligand, 2026 Share and CAGR (2026-2036)
  • Figure 25. Global Radioligand Therapy Market, By Radionuclide, 2026 Share and CAGR (2026-2036)
  • Figure 26. Key Therapeutic Radionuclides Used in Radioligand Therapy
  • Figure 27. Global Radioligand Therapy Market, By Radiation Type, 2026 Share and CAGR (2026-2036)
  • Figure 28. Global Radioligand Therapy Market, By Molecular Target, 2026 Share and CAGR (2026-2036)
  • Figure 29. Global Radioligand Therapy Market, By Indication, 2026 Share and CAGR (2026-2036)
  • Figure 30. Global Radioligand Therapy Market, By Treatment Line, 2026 Share and CAGR (2026-2036)
  • Figure 31. Global Radioligand Therapy Market, By End User, 2026 Share and CAGR (2026-2036)
  • Figure 32. Global Radioligand Therapy Market: Top 15 Countries/Sub-Regions, 2026 Vs. 2036 (USD Million)
  • Figure 33. North America: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
  • Figure 34. Europe: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
  • Figure 35. Asia-Pacific: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
  • Figure 36. Latin America: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
  • Figure 37. Middle East & Africa: Radioligand Therapy Market Snapshot, 2026-2036 (USD Million)
  • Figure 38. Key Growth Strategies Adopted By Leading Market Players (2023-2026)
  • Figure 39. Competitive Dashboard: Radioligand Therapy Market
  • Figure 40. Global Radioligand Therapy Market Ranking Analysis, By Key Player (2025)
  • Figure 41. Novartis AG: Financial Snapshot
  • Figure 42. Novartis AG: SWOT Analysis
  • Figure 43. Bayer AG: Financial Snapshot
  • Figure 44. Bayer AG: SWOT Analysis
  • Figure 45. Eli Lilly and Company: Financial Snapshot
  • Figure 46. Eli Lilly and Company: SWOT Analysis
  • Figure 47. Bristol Myers Squibb Company: Financial Snapshot
  • Figure 48. Bristol Myers Squibb Company: SWOT Analysis
  • Figure 49. AstraZeneca PLC: Financial Snapshot
  • Figure 50. AstraZeneca PLC: SWOT Analysis
  • Figure 51. Telix Pharmaceuticals Limited: Financial Snapshot
  • Figure 52. Telix Pharmaceuticals Limited: SWOT Analysis
  • Figure 53. ITM Isotope Technologies Munich SE: SWOT Analysis
  • Figure 54. Curium: SWOT Analysis
  • Figure 55. Lantheus Holdings, Inc.: Financial Snapshot
  • Figure 56. Lantheus Holdings, Inc.: SWOT Analysis
  • Figure 57. Perspective Therapeutics, Inc.: SWOT Analysis
  • Figure 58. Orano Med: SWOT Analysis
  • Figure 59. RadioMedix, Inc.: SWOT Analysis
  • Figure 60. Clarity Pharmaceuticals Ltd: SWOT Analysis
  • Figure 61. Sanofi: Financial Snapshot
  • Figure 62. Sanofi: SWOT Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!